Compare DexCom, Inc. (DXCM) vs Block Inc (XYZ) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

XYZ trades at $81.27, up 1.6% today, with a bullish technical outlook and strong analyst consensus. Recent Q1 2026 earnings beat expectations, though net income margin compressed to 3.3%. Cash App and Square drive growth, but a $45 million fraud settlement and rising credit losses pose headwinds. The stock is near its pivot point of $82, with resistance at $84.

The outlook is positive given earnings momentum and AI integration, but valuation remains elevated at a P/E of 63.91. Risks include regulatory scrutiny and margin pressure. Analysts see 8.9% upside to the $88.53 target, with 74% recommending buys. Institutional sentiment favors long-term growth despite near-term volatility.